{"protocolSection":{"identificationModule":{"nctId":"NCT05008588","orgStudyIdInfo":{"id":"CT/STROKE/PSI/2021"},"organization":{"fullName":"PT. Prodia Stem Cell Indonesia","class":"INDUSTRY"},"briefTitle":"Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct","officialTitle":"Safety and Efficacy of Combined Conditioned Medium With Umbilical Cord Mesenchymal Stem Cells as A Novel Strategy for Acute Stroke Infarct"},"statusModule":{"statusVerifiedDate":"2022-09","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-05-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2023-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-08-01","studyFirstSubmitQcDate":"2021-08-09","studyFirstPostDateStruct":{"date":"2021-08-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-09-23","lastUpdatePostDateStruct":{"date":"2022-09-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"PT. Prodia Stem Cell Indonesia","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study was to determine the effectiveness of a combination of intranasal conditioned medium (CM) with intraparenchymal umbilical cord mesenchymal stem cells (UC-MSCs) transplantation in acute stroke patients to induce neurogenesis.","detailedDescription":"This study has 3 arms namely CM and UC-MSCs treatment, UC-MSCs treatment only, and control. The investigator hypothesized that group of CM and UC-MSCs combination is the optimal treatment to induce neurogenesis in stroke patients."},"conditionsModule":{"conditions":["Ischemic Stroke"],"keywords":["Ischemic stroke","Mesenchymal Stem Cells","Conditioned Medium","Secretome"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"FACTORIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":15,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment","type":"EXPERIMENTAL","description":"Intranasal of 3 cc of conditioned medium each, for 3 days in a row and Intra-parenchymal transplantation of 20x10\\^6 UC-MSCs","interventionNames":["Biological: Conditioned Medium","Biological: Umbilical Cord Mesenchymal Stem Cells"]},{"label":"Umbilical cord mesenchymal stem cells treatment","type":"EXPERIMENTAL","description":"Intra-parenchymal transplantation of 20x10\\^6 UC-MSCs","interventionNames":["Biological: Umbilical Cord Mesenchymal Stem Cells"]},{"label":"Standard treatment (control)","type":"ACTIVE_COMPARATOR","description":"Neurologic and Neutrophic Drugs","interventionNames":["Procedure: Neurologic and Neutrophic Drugs"]}],"interventions":[{"type":"BIOLOGICAL","name":"Conditioned Medium","description":"Intranasal of 3 cc of conditioned medium each, for 3 days in a row","armGroupLabels":["Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment"],"otherNames":["Secretome"]},{"type":"BIOLOGICAL","name":"Umbilical Cord Mesenchymal Stem Cells","description":"Intra-parenchymal transplantation of 20x10\\^6 UC-MSCs","armGroupLabels":["Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment","Umbilical cord mesenchymal stem cells treatment"],"otherNames":["Mesenchymal stromal cells"]},{"type":"PROCEDURE","name":"Neurologic and Neutrophic Drugs","description":"Such as clopidogrel, piracetam, citicoline","armGroupLabels":["Standard treatment (control)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change from baseline Brain-Derived Neutrophic Factor at one month, 3 months and 6 months after transplantation","description":"Venous blood collection","timeFrame":"Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment"},{"measure":"Change from baseline Vascular endothelial growth factor at one month, 3 months and 6 months after transplantation","description":"Venous blood collection","timeFrame":"Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment"},{"measure":"Change baseline Magnetic Resonance Imaging at 6 month after transplantation","description":"To observe the brain development (neurogenesis)","timeFrame":"Before treatment, 6 month after transplantation"}],"secondaryOutcomes":[{"measure":"The National Institute of Health Stroke Scale (NIHSS) Scoring","description":"The NIH Stroke Scale (NIHSS) is a 15-item scale that is a well-validated and prognostically important measure of stroke-related neurologic deficits in research and clinical care","timeFrame":"Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment"},{"measure":"modified Rankin Scale (mRS)","description":"The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke","timeFrame":"Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female aged 25-60 years diagnosed with ischemic stroke acute phase\n* The patient has had a CT scan/MRI of the brain to assess ischemic territory\n* The patient must have an NIH Stroke score of 8-20\n* The patient or legal assistant has obtained detailed informed consent regarding the study protocol and agreeing to participate in the study\n* Patients with The Glasgow Coma Scale (GCS) score \\> 8\n* Patients with Pt-APTT values within normal limits\n\nExclusion Criteria:\n\n* Patients with recurrent stroke in the 6 months preceding the episode current stroke\n* CT or MRI images show midline shift and bleeding transformation\n* Participate in similar studies using CM and/or UC-MSC\n* Patients who are immunocompromised and/or who are receiving therapy immunosuppressive\n* Patients who cannot have a CT or MRI examination due to their condition\n* Patients with impaired renal and hepatic function after the onset of ischemic stroke: Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase (SGPT) \\> 5x the upper limit of normal values and a significant increase in urea-creatinine values\n* Patients with a history of malignant tumors or other severe neurologic conditions.","healthyVolunteers":false,"sex":"ALL","minimumAge":"25 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Muhammad Agus Aulia","role":"CONTACT","phone":"+6281283606327","email":"asct.prostem@gmail.com"}],"overallOfficials":[{"name":"Rima Haifa","affiliation":"Prodia StemCell Indonesia","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Gatot Soebroto Hospital","status":"RECRUITING","city":"Jakarta Pusat","state":"DKI Jakarta","zip":"10410","country":"Indonesia","contacts":[{"name":"Muhammad Agus Aulia, dr","role":"CONTACT","phone":"+6281283606327","email":"asct.prostem@gmail.com"},{"name":"Muhammad Agus Aulia, dr","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":-6.1818,"lon":106.8223}},{"facility":"PT Prodia StemCell Indonesia","status":"RECRUITING","city":"Jakarta","country":"Indonesia","geoPoint":{"lat":-6.21462,"lon":106.84513}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M1669","name":"Clopidogrel","relevance":"LOW"},{"id":"M6461","name":"Cytidine Diphosphate Choline","relevance":"LOW"},{"id":"M13470","name":"Piracetam","relevance":"LOW"}],"browseBranches":[{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"NootAg","name":"Nootropic Agents"},{"abbrev":"NeuroAg","name":"Neuroprotective Agents"}]}},"hasResults":false}